---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-030968"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:41:20.007845+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B

## Summary
- Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.
- Novo Nordisk gains exclusive global rights to develop and commercialize MASP-3 inhibitor zaltenibart in all indications.
- Omeros will use part of upfront to repay $67.1M term loan; remaining funds support narsoplimab approval and preclinical pipeline.
- Transaction expected to close Q4 2025, subject to HSR clearance and customary conditions.

## SEC filing metadata
- accession: 0001437749-25-030968
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925030968/0001437749-25-030968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925030968/omer20251014_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-030968
- JSON: https://secwatch.observer/filing/0001437749-25-030968.json
- Plain text: https://secwatch.observer/filing/0001437749-25-030968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.